New unveils US weight loss drug test results

Novo Nordisk presented full results from initial test phases of amycretin at a diabetes conference in Chicago. Amycretin aided weight loss of over 24%. Tests showed that overweight patients lost 22% after 36 weeks with a 20 mg dose, and 24.3% with a 60 mg dose. In pill form, a 12-week regime resulted in 10.4% weight loss at 50 mg, and 13.1% at 100 mg. Side effects mainly affected the gastrointestinal system, comparable to other weight loss drugs. Dosing adjustments are under consideration. Novo Nordisk anticipates initiating phase 3 trials of amycretin in 2026, aiming for approval in overweight and obesity treatment. Concurrently, Novo Nordisk develops Cagrisema, which resulted in a 22.7% weight loss, combining semaglutide and cagrilintid.